400 related articles for article (PubMed ID: 26306903)
1. Targeting the WNT Signaling Pathway in Cancer Therapeutics.
Tai D; Wells K; Arcaroli J; Vanderbilt C; Aisner DL; Messersmith WA; Lieu CH
Oncologist; 2015 Oct; 20(10):1189-98. PubMed ID: 26306903
[TBL] [Abstract][Full Text] [Related]
2. Targeting the Wnt/β-catenin signaling pathway in cancer.
Zhang Y; Wang X
J Hematol Oncol; 2020 Dec; 13(1):165. PubMed ID: 33276800
[TBL] [Abstract][Full Text] [Related]
3. Wnt/beta-catenin pathway: modulating anticancer immune response.
Pai SG; Carneiro BA; Mota JM; Costa R; Leite CA; Barroso-Sousa R; Kaplan JB; Chae YK; Giles FJ
J Hematol Oncol; 2017 May; 10(1):101. PubMed ID: 28476164
[TBL] [Abstract][Full Text] [Related]
4. Perspectives on the role of Wnt biology in cancer.
Mirabelli CK; Nusse R; Tuveson DA; Williams BO
Sci Signal; 2019 Jul; 12(589):. PubMed ID: 31289213
[TBL] [Abstract][Full Text] [Related]
5. New avenues to target Wnt/β-catenin signaling.
Verkaar F; Zaman GJ
Drug Discov Today; 2011 Jan; 16(1-2):35-41. PubMed ID: 21111060
[TBL] [Abstract][Full Text] [Related]
6. Wnt/β-Catenin Signaling Pathway as Chemotherapeutic Target in Breast Cancer: An Update on Pros and Cons.
Mukherjee N; Panda CK
Clin Breast Cancer; 2020 Oct; 20(5):361-370. PubMed ID: 32416986
[TBL] [Abstract][Full Text] [Related]
7. Targeting the Canonical WNT/β-Catenin Pathway in Cancer Treatment Using Non-Steroidal Anti-Inflammatory Drugs.
Vallée A; Lecarpentier Y; Vallée JN
Cells; 2019 Jul; 8(7):. PubMed ID: 31311204
[TBL] [Abstract][Full Text] [Related]
8. Wnt pathway modulators in cancer therapeutics: An update on completed and ongoing clinical trials.
Neiheisel A; Kaur M; Ma N; Havard P; Shenoy AK
Int J Cancer; 2022 Mar; 150(5):727-740. PubMed ID: 34536299
[TBL] [Abstract][Full Text] [Related]
9. Targeting the Versatile Wnt/β-Catenin Pathway in Cancer Biology and Therapeutics: From Concept to Actionable Strategy.
Dzobo K; Thomford NE; Senthebane DA
OMICS; 2019 Nov; 23(11):517-538. PubMed ID: 31613700
[TBL] [Abstract][Full Text] [Related]
10. Modulation of Wnt/β-catenin signaling pathway by bioactive food components.
Tarapore RS; Siddiqui IA; Mukhtar H
Carcinogenesis; 2012 Mar; 33(3):483-91. PubMed ID: 22198211
[TBL] [Abstract][Full Text] [Related]
11. E7386, a Selective Inhibitor of the Interaction between β-Catenin and CBP, Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt Signaling.
Yamada K; Hori Y; Inoue S; Yamamoto Y; Iso K; Kamiyama H; Yamaguchi A; Kimura T; Uesugi M; Ito J; Matsuki M; Nakamoto K; Harada H; Yoneda N; Takemura A; Kushida I; Wakayama N; Kubara K; Kato Y; Semba T; Yokoi A; Matsukura M; Odagami T; Iwata M; Tsuruoka A; Uenaka T; Matsui J; Matsushima T; Nomoto K; Kouji H; Owa T; Funahashi Y; Ozawa Y
Cancer Res; 2021 Feb; 81(4):1052-1062. PubMed ID: 33408116
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic potential of targeting the Wnt/β-catenin signaling pathway in colorectal cancer.
Cheng X; Xu X; Chen D; Zhao F; Wang W
Biomed Pharmacother; 2019 Feb; 110():473-481. PubMed ID: 30530050
[TBL] [Abstract][Full Text] [Related]
13. Change in gene expression profiles of secreted frizzled-related proteins (SFRPs) by sodium butyrate in gastric cancers: induction of promoter demethylation and histone modification causing inhibition of Wnt signaling.
Shin H; Kim JH; Lee YS; Lee YC
Int J Oncol; 2012 May; 40(5):1533-42. PubMed ID: 22246241
[TBL] [Abstract][Full Text] [Related]
14. Advances in targeting the WNT/β-catenin signaling pathway in cancer.
Chatterjee A; Paul S; Bisht B; Bhattacharya S; Sivasubramaniam S; Paul MK
Drug Discov Today; 2022 Jan; 27(1):82-101. PubMed ID: 34252612
[TBL] [Abstract][Full Text] [Related]
15. Recent Development of Wnt Signaling Pathway Inhibitors for Cancer Therapeutics.
Harb J; Lin PJ; Hao J
Curr Oncol Rep; 2019 Feb; 21(2):12. PubMed ID: 30715618
[TBL] [Abstract][Full Text] [Related]
16. Wnt signaling in cancer.
Zhan T; Rindtorff N; Boutros M
Oncogene; 2017 Mar; 36(11):1461-1473. PubMed ID: 27617575
[TBL] [Abstract][Full Text] [Related]
17. The potential of targeting Wnt/β-catenin in colon cancer.
Sebio A; Kahn M; Lenz HJ
Expert Opin Ther Targets; 2014 Jun; 18(6):611-5. PubMed ID: 24702624
[TBL] [Abstract][Full Text] [Related]
18. MiR-1207 overexpression promotes cancer stem cell-like traits in ovarian cancer by activating the Wnt/β-catenin signaling pathway.
Wu G; Liu A; Zhu J; Lei F; Wu S; Zhang X; Ye L; Cao L; He S
Oncotarget; 2015 Oct; 6(30):28882-94. PubMed ID: 26337084
[TBL] [Abstract][Full Text] [Related]
19. Wnt/beta-catenin signaling pathway as a novel cancer drug target.
Luu HH; Zhang R; Haydon RC; Rayburn E; Kang Q; Si W; Park JK; Wang H; Peng Y; Jiang W; He TC
Curr Cancer Drug Targets; 2004 Dec; 4(8):653-71. PubMed ID: 15578921
[TBL] [Abstract][Full Text] [Related]
20. C644-0303, a small-molecule inhibitor of the Wnt/β-catenin pathway, suppresses colorectal cancer growth.
Yan Y; Zhang Y; Li M; Zhang Y; Zhang X; Zhang X; Xu Y; Wei W; Wang J; Xu X; Song Q; Zhao C
Cancer Sci; 2021 Nov; 112(11):4722-4735. PubMed ID: 34431598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]